Compare Torrent Pharma with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs IPCA LABS - Comparison Results

TORRENT PHARMA     Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA IPCA LABS TORRENT PHARMA/
IPCA LABS
 
P/E (TTM) x 37.0 23.2 159.4% View Chart
P/BV x 9.4 8.3 112.8% View Chart
Dividend Yield % 0.6 0.1 445.5%  

Financials

 TORRENT PHARMA   IPCA LABS
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-19
IPCA LABS
Mar-19
TORRENT PHARMA/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs1,9641,042 188.5%   
Low Rs1,245590 211.0%   
Sales per share (Unadj.) Rs453.4298.6 151.8%  
Earnings per share (Unadj.) Rs25.835.0 73.7%  
Cash flow per share (Unadj.) Rs62.349.4 126.0%  
Dividends per share (Unadj.) Rs17.003.00 566.7%  
Dividend yield (eoy) %1.10.4 288.2%  
Book value per share (Unadj.) Rs279.2247.1 113.0%  
Shares outstanding (eoy) m169.22126.35 133.9%   
Bonus/Rights/Conversions -ESOS-  
Price / Sales ratio x3.52.7 129.5%   
Avg P/E ratio x62.223.3 266.9%  
P/CF ratio (eoy) x25.816.5 156.1%  
Price / Book Value ratio x5.73.3 174.0%  
Dividend payout %65.98.6 769.2%   
Avg Mkt Cap Rs m271,513103,108 263.3%   
No. of employees `00013.613.4 101.2%   
Total wages/salary Rs m14,0387,874 178.3%   
Avg. sales/employee Rs Th5,642.62,807.0 201.0%   
Avg. wages/employee Rs Th1,032.4585.8 176.2%   
Avg. net profit/employee Rs Th320.9329.0 97.5%   
INCOME DATA
Net Sales Rs m76,72837,732 203.4%  
Other income Rs m571577 98.9%   
Total revenues Rs m77,29938,309 201.8%   
Gross profit Rs m19,8316,901 287.4%  
Depreciation Rs m6,1771,824 338.6%   
Interest Rs m5,038189 2,669.6%   
Profit before tax Rs m9,1875,465 168.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-3,5700-   
Tax Rs m1,2541,042 120.3%   
Profit after tax Rs m4,3634,422 98.7%  
Gross profit margin %25.818.3 141.3%  
Effective tax rate %13.619.1 71.5%   
Net profit margin %5.711.7 48.5%  
BALANCE SHEET DATA
Current assets Rs m50,37523,778 211.9%   
Current liabilities Rs m51,65310,975 470.6%   
Net working cap to sales %-1.733.9 -4.9%  
Current ratio x1.02.2 45.0%  
Inventory Days Days92104 88.7%  
Debtors Days Days6866 103.6%  
Net fixed assets Rs m83,64820,368 410.7%   
Share capital Rs m846253 334.9%   
"Free" reserves Rs m46,39730,971 149.8%   
Net worth Rs m47,24431,224 151.3%   
Long term debt Rs m39,1291,409 2,778.1%   
Total assets Rs m141,20945,507 310.3%  
Interest coverage x2.830.0 9.4%   
Debt to equity ratio x0.80 1,836.1%  
Sales to assets ratio x0.50.8 65.5%   
Return on assets %6.710.1 65.7%  
Return on equity %9.214.2 65.2%  
Return on capital %12.317.3 71.2%  
Exports to sales %045.9 0.0%   
Imports to sales %016.6 0.0%   
Exports (fob) Rs mNA17,308 0.0%   
Imports (cif) Rs mNA6,266 0.0%   
Fx inflow Rs m22,10317,308 127.7%   
Fx outflow Rs m5,5226,266 88.1%   
Net fx Rs m16,58111,042 150.2%   
CASH FLOW
From Operations Rs m17,9814,923 365.3%  
From Investments Rs m-2,413-1,563 154.4%  
From Financial Activity Rs m-13,145-1,832 717.5%  
Net Cashflow Rs m2,3801,528 155.8%  

Share Holding

Indian Promoters % 71.5 45.9 155.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.0 11.4 61.6%  
FIIs % 12.6 25.3 49.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 17.4 50.6%  
Shareholders   26,511 36,892 71.9%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   GSK PHARMA  JUBILANT PHARMOVA   BIOCON   STERLING BIOTECH  NATCO PHARMA  

Compare TORRENT PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 257 Points Higher; Tata Steel & Hindalco Among Top Nifty Gainers(Closing)

Indian share markets witnessed positive trading activity throughout the day today and ended higher.

Related Views on News

IPCA LABS Announces Quarterly Results (3QFY21); Net Profit Up 32.2% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, IPCA LABS has posted a net profit of Rs 3 bn (up 32.2% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 27.0% (Quarterly Result Update)

Oct 27, 2020 | Updated on Oct 27, 2020

For the quarter ended September 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 27.0% YoY). Sales on the other hand came in at Rs 20 bn (up 0.6% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY21); Net Profit Up 243.5% (Quarterly Result Update)

Sep 29, 2020 | Updated on Sep 29, 2020

For the quarter ended June 2020, IPCA LABS has posted a net profit of Rs 5 bn (up 243.5% YoY). Sales on the other hand came in at Rs 15 bn (up 46.9% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 48.6% (Quarterly Result Update)

Jul 31, 2020 | Updated on Jul 31, 2020

For the quarter ended June 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 48.6% YoY). Sales on the other hand came in at Rs 21 bn (up 1.7% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 22.8% YoY). Sales on the other hand came in at Rs 11 bn (up 20.2% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Sell in May and Go Away?(Fast Profits Daily)

Apr 28, 2021

Does the concept of selling stocks in the month of May, work in the Indian market?

This Fund Manager Has Taken the World by Storm. Will You Invest With Her?(Profit Hunter)

Apr 26, 2021

Should you invest with this Rockstar fund manager who has outperformed in a big way?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


May 7, 2021 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 8-QTR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS